Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents

applications for composition of matter and methods of treatment in major markets worldwide. These patents and patent applications, if granted, are expected to provide us with intellectual property protection for all of our current product candidates until 2030 and beyond. We intend to continue to expand our intellectual property protections by seeking and maintaining domestic and international patents on inventions that are commercially important to our business. We will also rely on know-how and continuing technological innovation to develop and maintain our proprietary position.

Our Strategy

        Our goal is to leverage our leadership in structure-based drug discovery to deliver first- or best-in-class small molecule compounds to patients in diseases that represent large market opportunities where there are significant unmet medical needs.

        The key elements of our business strategy are to:

    Advance our growing portfolio of product candidates.  We have discovered internally a pipeline of novel product candidates in a variety of important disease areas, including VTP-34072 for type 2 diabetes / metabolic syndrome, VTP-37948 for Alzheimer's, VTP-43742 for autoimmune disorders, VTP-38443 for acute coronary syndrome, VTP-38543 for atopic dermatitis and have recently initiated a discovery program in immuno-oncology. We have entered into separate collaborations with BI to advance VTP-34072 and VTP-37948. We intend to retain rights to VTP-43742, VTP-38443 and VTP-38543, which we believe we can effectively advance through the next phase of clinical development.
    Establish late-stage development and commercialization capabilities for certain of our product candidates in the United States and potentially other markets.  We intend to retain rights to and advance product candidates in certain therapeutic and geographic areas where we believe that we can effectively further develop and, if approved, commercialize a product candidate. For example, we intend to progress VTP-43742 for autoimmune disorders in the United States because we believe that many potential autoimmune disorders are treated by specialist physicians who could be reached by a focused commercial organization.
    Selectively collaborate with large biotechnology and pharmaceutical companies to maximize the value of our product candidates.  We intend to continue to seek opportunities to collaborate with large pharmaceutical and biotechnology companies for certain therapeutic areas and geographies where we can leverage our collaborators' development, regulatory and commercial expertise to maximize the value of our product candidates. We currently have two collaborations, both with BI, from which, through June 30, 2014, we have received $152.4 million, including upfront license fees, research funding and success-based milestone payments as well as equity investments. These collaborations have enhanced the progress of our type 2 diabetes and Alzheimer's programs and given us access to BI's global commercialization infrastructure to pursue these large market opportunities.
    Leverage Contour, our proprietary structure-based drug discovery platform, to rapidly discover novel small molecule product candidates for additional validated, difficult-to-drug targets.  We plan to continue to apply Contour to targets that have significant unmet medical needs and well validated biology, but which have traditionally been considered difficult-to-drug. We believe targets with validated biology, achieved through genetics, animal data and direct clinical experience, increase the probability of success of our discoveries. Difficult-to-drug targets provide an opportunity to leverage our structure-based drug discovery capabilities with Contour to overcome significant discovery obstacles, including potency, selectivity, pharmacokinetics properties and novelty, and to discover and advance new product candidates with first- or best-in-class potential. We expect that using Contour and applying these selection criteria will result in the discovery and development of product candidates with the potential to have significant competitive advantages.

77